Ebalzotan (NAE-086) is a selective 5-HT1A receptor agonist.[1][2] It was under development as an antidepressant and anxiolytic agent but produced undesirable side effects in phase I clinical trials and was subsequently discontinued.[1][2]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C19H30N2O2 |
Molar mass | 318.461 g·mol−1 |
3D model (JSmol) |
|
|